Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regeneus has announced positive results from its preclinical trial of Progenza
  • Researchers gave injections using Progenza to a rat for 14 days and it reversed the allodynia in the animal
  • The preclinical results showed significant potential for Progenza to be used in human trials

Regeneus has announced positive results from its preclinical trial of Progenza.

Progenza is a treatment for allodynia, a condition in which pain occurs from what is normally non-painful stimulation of the skin, such as light touch.

The trial was completed with the University of Adelaide by Professor Mark Hutchinson.

Results of the preclinical trial was studied on a rat, which allowed for the graded measurement of neuropathic pain to match human neuropathic pain conditions.

Researchers gave injections using Progenza to the rat for 14 days and it reversed the allodynia in the animal.

The preclinical results showed significant potential for Progenza in the treatment of neuropathic pain.

Mark believes it is uncommon to identify treatments that reverse pain like Progenza did.

“Progenza was capable of this long-term complete reversal of the exaggerated pain behaviour. This is the type of a treatment response that is highly desirable for a new therapy,” he said.

Regeneus is an Australian clinical-stage regenerative medicine company, focusing on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

Non-Executive Director, Dr Alan Dunton is pleased with the results.

“Studies like this support the development of Progenza for treating neuropathic pain where very few options exist,” he said.

The new results supports the company’s growth strategy targeting the global neuropathic pain market, which currently has limited successful treatment options.

The global neuropathic pain industry is estimated to be worth US$69 billion and is expected to reach US$79 billion by 2024.

Shares have remained steady since yesterday trading for 10.5 cents with a market cap of $21.93 million.

RGS by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.